Mendelian Reports High Cost of Rare Disease Patients
Executive Summary
New research commissioned by health tech company Mendelian found that rare disease patients have cost NHS England in excess of £4.3bn over the past ten years. The company is hoping its technology can enable physicians and hospitals to save money and diagnose patients faster.
You may also be interested in...
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
Abbott Surprises Analysts With CE Mark For Freestyle Libre 3
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.